Rapid Acceleration of Diagnostics (RADx) Program Tech Project: 2180 AscencioDX - Low-cost Moderate-throughput COVID-19 Test to Support Massive Test Scaleup at Small Clinics and Community Sites
Award Notice Posted
- Solicitation number
- 75N92022C00005
- Agency
-
National Heart Lung and Blood Institute
National Institutes of Health, Department of Health and Human Services
- Awarded
- to ADL Diagnostics, Inc.
- Set-aside
- No set-aside
Opportunity facts
- Contract number
- 75N92022C00005 Federal contract award
- NAICS code
- 334516 Analytical Laboratory Instrument Manufacturing
- PSC
- Q301 Reference Laboratory Testing
- Place of performance
- Woodinville, Washington 98077, United States
Notice details come from SAM.gov. Updated .
About this opportunity
This Award Notice from the Department of Health and Human Services National Institutes of Health National Heart Lung and Blood Institute announced a sole source, firm fixed price contract valued at $14.9 million to ADL Diagnostics, Inc. trading as Anavasi Diagnostics. The contract is to complete validation of Anavasi's AscencioDX rapid point-of-care molecular COVID-19 test, obtain Emergency Use Authorization from the FDA, and scale up manufacturing to produce testing kits capable of processing 25 tests per hour to support the RADx initiative's goal of widespread COVID-19 testing from October 25, 2021 to October 24, 2022.
Notice text
This acquisition was not synopsized in the Beta.Sam and was awarded under the authority of 41 U.S.C 253(c)(1) as set forth in FAR 6.302-3, Industrial Mobilization. A firm fixed price type contract was awarded.
Awarded contract 75N92022C00005 to ADL Diagnostics, Inc. for 14900000.00 on 2021-11-05.
Files
| File | Type | Posted |
|---|---|---|
| Justification and Approval Anavasi updated 10-15-21 djf 10-22-21.pdf |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity